Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin

British Journal of Clinical Pharmacology

Volumn 56, Issue 6, 2003, Pages 670-678

  Kumana, Cyrus R ^a   Tong, Matthew K L ^b   Li, Chun Sang ^c   Lauder, Ian J ^a   Lee, Joseph S K ^d   Kou, Maybelle ^a   Walley, Tom ^e   Haycox, Alan ^e   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d QUEEN MARY HOSPITAL   (Hong Kong)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cost effectiveness analysis; Cyclosporin Neoral ; Diltiazem; Dosage conservation; Double blind randomized trial

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COST; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET FORMULATION;

ADOLESCENT; ADULT; AGED; COST SAVINGS; CYCLOSPORINE; DILTIAZEM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUALITY OF LIFE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0344081242     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01908.x     Document Type: Article

References (34)

1. Kronbach T, Fisher V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635.
2. Shaw LM. Advances in cyclosporine pharmacology, measurement and therapeutic monitoring. Clin Chem 1989; 35: 1299-1308.
3. Lindholm A, Henricsson S, Dahlqvist R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 1990; 29: 541-548.
4. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
5. Herbert MF, Roberts JP, Pfueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
6. Wood AJ, Maurer G, Niederberger W, Beveridge T. Cyclosporine: pharmacokinetics metabolism and drug interactions. Transplant Proc 1983; 15 (Suppl 1): 2409-2412.
7. Schwinghammer TL, Przepiorka D, Venkataramanan R et al. The kinetics of cyclosporin and its metabolites in bone marrow transplant patients. Br J Clin Pharmacol 1991; 32: 323-328.
8. Aweeka FT, Tamlanovich SJ, Prueksuritanont T, Gupta SK, Benet LZ. Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol 1994; 34: 60-67.
9. Chabannes D, Moreau JF, Soulillou JP. Effect of cyclosporine, cyclosporine metabolite 17, and other cyclosporine-related compounds on T lymphocyte clones derived from rejected human kidney grafts. I. Inhibition of proliferation. Transplantation 1987; 44: 813-817.
10. Ryffell B, Foxwell BM, Mihatsch MJ, Donatsch P, Maurer G. Biologic significance of cyclosporine metabolites. Transplant Proc 1988; 20 (Suppl 2): 575-584.
11. Babany G, Morris RE, Babany I, Shepherd S, Kates RE. In vivo evaluation of the effects of altered cyclosporine metabolism on its immunosuppressive potency. J Pharmacol Exp Ther 1989; 248: 893-899.
12. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Parts I & II). Clin Pharmacokinet 1990; 19: 319-332, 400-415.
13. First MR, Schroeder TJ, Michael A, Hariharan S, Weiskittel P, Alexander JW. Safety and efficacy of long-term cyclosporine-ketoconazole administration and preliminary results of a randomized trial. Transplant Proc 1993; 25: 591-594.
14. Duchame MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-491.
15. Epstein M. Calcium antagonists and renal protection. Current status and future perspectives. Arch Intern Med 1992; 152: 1573-1584.
16. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin. An update. Clin Pharmacokinet 1996; 30: 141-179.
17. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997; 32: 357-367.
18. Martin JE, Daoud A, Schroeder TJ, First AR. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317-337.
19. Jones TE. Survey of cyclosporin-sparing agent use in Australasian transplant centers. Aust NZ J Med 1996; 26: 772-776.
20. McDonald SP, Russ GR. Associations between cyclosporine-sparing agents and outcomes in kidney transplant recipients. Kidney Int 2002; 61: 2259-2265.
21. Leibbrandt DM, Day RO. Cyclosporin and calcium channel blockers: an exploitable drug interaction? Med J Aust 1992; 157: 296-297.
22. Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8: 128-133.
23. Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DWA. Clinical and medicoeconomic impact of cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994; 14: 471-481.
24. Proceeding of the symposium on the Neoral Formula of Cyclosporin. Transplant Proc 1994; 26: 2925-2996.
25. Asberg A, Christensen H, Hartmann A, Carlson E, Molden E, Berg KJ. Pharmacokinetic interactions between microemulsion formulated cyclosporin A and diltiazem in renal transplant recipients. Eur J Clin Pharmacol 1999; 55: 383-387.
26. Shield CF 3rd, Jacobs RJ, Wyant S, Das A. A cost effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kid Dis 1996; 27: 855-864.
27. Ware JE Jr. SF-36 health survey: manual and interpretation guide, 2nd Printing. Boston: Nimrod Press, 1997; 3,1-10,13.
28. Lam CL, Gandek B, Ren XS, Chan MS. Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1139-1147.
29. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporin-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-3957.
30. Kelly JJ, Walker RG, d'Apice AJF, Kincaid-Smith P. A prospective study of the effect of diltiazem in renal allograft recipients receiving cyclosporin A: preliminary results. Transplant, Proc 1990; 22: 2127-2128.
31. Chrysostomou A, Walker RG, Russ GR, d'Apice AJ, Kincaid-Smith P, Mathew TH. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300-304.
32. Ladefoged SD, Pedersen E, Hammer M, Rasmussen KC, Hansen FM, Andersen CB. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 1994; 9: 543-547.
33. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction - dose-response relationship. Br J Clin Pharmacol 1997; 44: 499-504.
34. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsions-based formulation (neoral) 1 in organ transplantation. Drugs 2001; 61: 1957-2016.